EU, Novavax sign deal for 200 million COVID-19 jabs
The European Commission approved on Wednesday the purchase of 100 million doses of Novavax Inc.’s vaccine against COVID-19, with an option to acquire an additional 100 million throughout 2023.
“With clinical data from our trials showing strong efficacy against variants of concern and variants of interest, we believe that our vaccine candidate will play a critical role in the effort to help control the pandemic in the EU and other regions in the world,” Novavax President and Chief Executive Officer (CEO) Stanley Erck commented.
Novavax recently announced the phase 3 of the study of its vaccine showed it is 90.4% effective against coronavirus.
Get involved!
Comments